Dr. Divya S. Mishra is a Board-Certified Oncologist with over 18 years of experience spanning clinical practice, clinical research, medical affairs, pharma industry leadership, and academia. Currently, she is working as Medical Director at ICON plc with responsibility for oversight of global clinical trials in Oncology and Hematology. Prior to ICON, she held senior roles at Pfizer, SFJ Inc., and Quintiles (now IQVIA), leading medical strategy, trial oversight, and product lifecycle management for oncology products across multiple regions.
With a strong focus on driving strategic initiatives to enhance efficiencies across clinical research and healthcare settings, Dr. Divya has been assiduously following developments in use of Artificial Intelligence in Healthcare and personalized medicine.
Dr. Divya is a passionate advocate for improving patient outcomes through innovative and targeted interventions while ensuring that better and safer medicines reach cancer patients worldwide.
Oncology, Clinical Trials, Outcomes Research
AI in Clinical Research in Oncology
Artificial Intelligence (AI) is revolutionizing cancer research, transforming the way we diagnose, treat, and predict disease outcomes. This talk explores the ongoing advancements in AI-driven oncology, highlighting breakthroughs in precision medicine, drug discovery, and patient care optimization. From AI-powered imaging and biomarker identification to machine learning models predicting treatment responses, these innovations are accelerating research timelines and improving patient outcomes. I will also discuss the integration of AI into clinical trials, streamlining data analysis and enhancing decision-making. While AI offers immense promise, challenges such as data privacy, bias, and regulatory hurdles remain critical considerations. By examining current progress, refining processes, and envisioning future predictions, this session aims to provide insights into the evolving role of AI in cancer research and its potential to reshape the landscape of oncology.